Drug Digest: Patient Preference Drives Solid Dosage Trends

In this exclusive Drug Digest video interview, Patrick Lavery, Editor, Pharmaceutical Technology® Group, interviews an industry expert about solid dosage formulation trends. During the discussion, the expert will detail what the challenges to developers are, what are currently some of the most frequently sought-after expert techniques, how contract development and manufacturing organizations (CDMOs) can leverage their experience in performing those techniques to improve oral solid dosage (OSD) bioavailability, and what the future holds in terms of advancements in OSD drug delivery.

Interview featuring

Adi Kaushal, Director and Technology Head, Bioavailability Enhancement, Lonza

Adi Kaushal is the Director and Technology Head for Bioavailability Enhancement (BAE) at Lonza Bend. He has over 20 years of formulation experience and has been with Lonza (previously Bend Research) since 2010. Adi is responsible for overall BAE technology strategy and progression of customer programs from feasibility to commercialization. Adi’s group of over 50 experienced scientists and engineers are engaged in bringing new BAE technologies to product development, customer-centric advancements, and continuous improvement of Lonza internal systems. Adi also supports collaboration with internal R&D within the Lonza Small Molecules business unit.

Sponsors

This episode of Drug Digest is sponsored by:

• Adare Pharma Solutions
• Catalent
• Coating Place Inc.
• gChem
• Ligand
• LGM Pharma
• Veltek Associates

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

• July/August 2025: Large-Molecule Manufacturing Trends
• September 2025: Developments in Small Molecule APIs, Excipients, and Ingredients
• October 2025: Partnering for BioPharma Success